CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients

European Journal of Haematology

Volumn 78, Issue 2, 2007, Pages 111-116

  Todisco, Elisabetta ^a   Castagna, Luca ^a   Sarina, Barbara ^a   Mazza, Rita ^a   Magagnoli, Massimo ^a   Balzarotti, Monica ^a   Nozza, Andrea ^a   Siracusano, Licia ^a   Timofeeva, Inna ^a   Anastasia, Antonella ^a   Demarco, Monica ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Growth factor; High dose chemotherapy; Lymphoma; Peripheral stem cells

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CARMUSTINE; CD34 ANTIGEN; CEFTAZIDIME; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LENOGASTRIM; MELPHALAN; MITOXANTRONE; NAVELBINE; PENICILLIN G; PIPERACILLIN; RITUXIMAB; TAZOBACTAM; THIOTEPA; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW CELL; CANCER CHEMOTHERAPY; CD34 SELECTION; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HISTOLOGY; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SEPTIC SHOCK; STATISTICAL SIGNIFICANCE; STOMATITIS; TRANSFUSION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; COHORT STUDIES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; FEVER; FILGRASTIM; GASTROINTESTINAL DISEASES; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; IFOSFAMIDE; INFECTION CONTROL; LENGTH OF STAY; LYMPHOMA; MALE; MIDDLE AGED; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33846059463     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00793.x     Document Type: Article

References (31)

1. Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high-dose therapy with hemopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999;17:423-9.
2. Linch DC, Milligan DW, Winfield DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997;99:933-8.
3. Schmitz N, Pfistner B, Sextro M, German Hodgkin's Lymphoma Study Group, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71.
4. Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353-7.
5. Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997;126:600-7.
6. Gisselbrecht C, Prentice HG, Bacigalupo A, et al. Placebo-controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 1994;343:696-700.
7. Tarella C, Castellino C, Locatelli F, et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998;21:401-7.
8. Klumpp TR, Mangan KF, Golderg SL, et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995;13:1323-7.
9. Lee SM, Radford JA, Dobson L, et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998;77:1294-9.
10. Spitzer G, Adkins DR, Spencer V, et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994;12:661- 70.
11. Dunlop DJ, Fitzsimons EJ, McMurray A, et al. Filgrastim fails to improve haematopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer 1994;70:943-5.
12. Kawano Y, Takaue Y, Mimaya J, et al. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood 1998;92:4040-6.
13. Cortelazzo S, Viero P, Bellavita P, et al. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplantation in non-Hodgkin's lymphoma. J Clin Oncol 1995;13:935-41.
14. Smith TJ, Khatcheressian J, Ozer LH, et al. American Society of Clinical Oncology. Update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85.
15. Faucher C, Le Corroller AG, Chabannon C, et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996;17:533-6.
16. Bolwell BJ, Pohlman B, Andresen S, et al. Delayed GCSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998;21:369-73.
17. Bence-Bruckler I, Bredeson C, Atkins H, et al. Randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998;22:965-9.
18. de Azevedo AM, Nucci M, Maiolino A, et al. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002;29:745-51.
19. To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood 1997;89:2233-58.
20. Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360-77.
21. Olivieri A, Offidani M, Montanari M, et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 1998;83:329-37.
22. Kiss JE, Rybka WB, Winkelstein A, et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997;19:303-10.
23. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
24. Rowe JM, Ciobanu N, Ascensao J, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med 1994;120:143-58.
25. McQuaker IG, Hunter AE, Pacey S, et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997;15:451-7.
26. Hornedo J, Sola C, Solano C, et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002;29:737-43.
27. Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, Bowers CE, Kronmueller N, Niemeyer R, McIntyre W. Randomised study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994;12:661- 70.
28. Dunn CJ, Goa KL. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 2000;59:681-717.
29. Shimazaki C, Oku N, Uchiyama H, et al. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1994;13:271-5.
30. Suh C, Kim HJ, Kim SH, et al. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Transfusion 2004;44:533-8.
31. Valteau-Couanet D, Faucher C, Auperin A, et al. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant 2005;36:547-52.